Clinical trial · Interventional
A Study of Tarceva (Erlotinib) Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)
An Open-label Study of the Effect of Tarceva Monotherapy on Treatment Response in Patients With Advanced Non-small Cell Lung Cancer for Whom Tarceva Monotherapy is Considered the Best Option
NCT01996332CI-TRIAL-00015049completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate the efficacy and safety of oral Tarceva in patients with advanced NSCLC for whom Tarceva monotherapy is considered the best therapeutic option. The anticipated time on study treatment is 3-12 months.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| erlotinib [Tarceva] | Drug | Erlotinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Tarceva Arm
- interventionNames
- Drug: erlotinib [Tarceva]
Primary outcomes (1)
- measure
- Time to Disease Progression or Death by Line of Treatment
- timeFrame
- Baseline, every 6-8 weeks up to 3 years until disease progression or death
- description
- Time to progression or death was defined as the time from inclusion to the date of disease progression or death, whichever occurred first.
Secondary outcomes (2)
- measure
- Percentage of Participants Achieving Clinical Benefit by Line of Treatment
- timeFrame
- Baseline, every 6-8 weeks up to 3 years or until death
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * adult patients \>=18 years of age; * locally advanced or metastatic NSCLC (Stage IIIB or IV); * not a candidate for curative surgery or radical chemotherapy; * no brain metastases, or clinically stable metastases for \>=2 months. Exclusion Criteria: * radiotherapy over the previous 2 weeks; * weight loss \>10% in the previous 6 weeks.
References
Publications (0)
Data not yet available
No reference posted for this study.